Market Cap 51.90B
Revenue (ttm) 30.24B
Net Income (ttm) 712.32M
EPS (ttm) N/A
PE Ratio 10.59
Forward PE 9.98
Profit Margin 2.36%
Debt to Equity Ratio 0.65
Volume 2,729,630
Avg Vol 2,779,876
Day's Range N/A - N/A
Shares Out 3.18B
Stochastic %K 83%
Beta 0.03
Analysts Sell
Price Target $18.10

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3278-2111
Fax: 81 3 3278-2000
Address:
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
jlz1
jlz1 Jan. 8 at 4:53 PM
$TAK 3.65% divi too!!!Lets goooo!! Should be a $20-30 + stock. Look at their strong financials!
0 · Reply
SantosSquire1021
SantosSquire1021 Jan. 6 at 5:18 PM
$CAH $MPC $CMG $TAK $ROP Nicely completed
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 6 at 2:26 PM
$ALMS GM, y'all. This is why conviction matters in biotech. Congrats to everyone who stuck with this one and actually did the homework. Today’s massive move reflects the market finally responding to definitive Phase 3 validation after months of disconnect between fundamentals and price. I laid out the bull case well before this readout; this morning simply confirms it. Quick breakdown of today’s ONWARD Phase 3 data: Key Phase 3 takeaways (ONWARD1 & ONWARD2): Both trials met all primary and secondary endpoints with high statistical significance ~74% PASI-75 and ~59% sPGA 0/1 by Week 16 By Week 24, responses deepened meaningfully: ~65% PASI-90 40% PASI-100 Rapid onset, with separation from placebo on PASI-90 as early as Week 4 Outperformed apremilast across all PASI endpoints (p < 0.0001) Safety and tolerability were clean and consistent with Phase 2 -- no new signals Co plans to submit an NDA in 2H 2026 What matters here is where this lands competitively. External commentary today framed envudeucitinib as competitive with -- and in some measures rivaling -- other late-stage oral psoriasis programs from $JNJ / $PTGX and $TAK Takeda. That’s the real benchmark -- and ALMS just put itself squarely in that conversation. This is the payoff when a late-stage biotech delivers on Phase 3 execution: strong efficacy, durability, competitive differentiation, and a clean safety profile -- delivered at scale across two global Phase 3 trials. Giddy up.
1 · Reply
Okadarlan
Okadarlan Jan. 6 at 12:05 PM
$TAK they have the financials and income of a company that should be trading at atleast 50-60 dollar, why is this so low ?
2 · Reply
TheRhew6
TheRhew6 Dec. 31 at 3:07 PM
$TAK no volume ..
0 · Reply
TheRhew6
TheRhew6 Dec. 30 at 7:26 PM
$TAK somebody like it with a stick. Let’s hit 17$ 🤙🏼
1 · Reply
Quantumup
Quantumup Dec. 30 at 1:19 PM
Guggenheim reiterated $UNCY Buy/$46 $SNY $MAZE $TVTX $TAK ARDX AKBA Here's what Guggenheim had to say: https://x.com/Quantumup1/status/2005990714652364820?s=20
1 · Reply
TheRhew6
TheRhew6 Dec. 29 at 8:43 PM
$SLS great profits today! Took half profits letting the rest ride. Moving on over to $TAK for the upcoming run.
0 · Reply
TheRhew6
TheRhew6 Dec. 29 at 8:30 PM
$TAK here’s my new winner! I’m in! Let’s run this up good luck to all.
1 · Reply
jlz1
jlz1 Dec. 29 at 5:38 PM
$TAK what is the new price target for TAK? $50?
0 · Reply
Latest News on TAK
US FDA investigates death tied to Takeda's blood disorder drug

Nov 21, 2025, 12:00 PM EST - 7 weeks ago

US FDA investigates death tied to Takeda's blood disorder drug


Takeda Pharmaceutical to exit cell therapy research

Oct 1, 2025, 9:41 AM EDT - 3 months ago

Takeda Pharmaceutical to exit cell therapy research


Shares of Asian drugmakers drop after Trump threatens tariffs

Sep 25, 2025, 10:52 PM EDT - 3 months ago

Shares of Asian drugmakers drop after Trump threatens tariffs


What's Going On With Takeda Stock On Friday?

Aug 22, 2025, 11:21 AM EDT - 5 months ago

What's Going On With Takeda Stock On Friday?


Takeda Announces New Assignments of Directors

Jun 25, 2025, 3:07 AM EDT - 7 months ago

Takeda Announces New Assignments of Directors


jlz1
jlz1 Jan. 8 at 4:53 PM
$TAK 3.65% divi too!!!Lets goooo!! Should be a $20-30 + stock. Look at their strong financials!
0 · Reply
SantosSquire1021
SantosSquire1021 Jan. 6 at 5:18 PM
$CAH $MPC $CMG $TAK $ROP Nicely completed
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 6 at 2:26 PM
$ALMS GM, y'all. This is why conviction matters in biotech. Congrats to everyone who stuck with this one and actually did the homework. Today’s massive move reflects the market finally responding to definitive Phase 3 validation after months of disconnect between fundamentals and price. I laid out the bull case well before this readout; this morning simply confirms it. Quick breakdown of today’s ONWARD Phase 3 data: Key Phase 3 takeaways (ONWARD1 & ONWARD2): Both trials met all primary and secondary endpoints with high statistical significance ~74% PASI-75 and ~59% sPGA 0/1 by Week 16 By Week 24, responses deepened meaningfully: ~65% PASI-90 40% PASI-100 Rapid onset, with separation from placebo on PASI-90 as early as Week 4 Outperformed apremilast across all PASI endpoints (p < 0.0001) Safety and tolerability were clean and consistent with Phase 2 -- no new signals Co plans to submit an NDA in 2H 2026 What matters here is where this lands competitively. External commentary today framed envudeucitinib as competitive with -- and in some measures rivaling -- other late-stage oral psoriasis programs from $JNJ / $PTGX and $TAK Takeda. That’s the real benchmark -- and ALMS just put itself squarely in that conversation. This is the payoff when a late-stage biotech delivers on Phase 3 execution: strong efficacy, durability, competitive differentiation, and a clean safety profile -- delivered at scale across two global Phase 3 trials. Giddy up.
1 · Reply
Okadarlan
Okadarlan Jan. 6 at 12:05 PM
$TAK they have the financials and income of a company that should be trading at atleast 50-60 dollar, why is this so low ?
2 · Reply
TheRhew6
TheRhew6 Dec. 31 at 3:07 PM
$TAK no volume ..
0 · Reply
TheRhew6
TheRhew6 Dec. 30 at 7:26 PM
$TAK somebody like it with a stick. Let’s hit 17$ 🤙🏼
1 · Reply
Quantumup
Quantumup Dec. 30 at 1:19 PM
Guggenheim reiterated $UNCY Buy/$46 $SNY $MAZE $TVTX $TAK ARDX AKBA Here's what Guggenheim had to say: https://x.com/Quantumup1/status/2005990714652364820?s=20
1 · Reply
TheRhew6
TheRhew6 Dec. 29 at 8:43 PM
$SLS great profits today! Took half profits letting the rest ride. Moving on over to $TAK for the upcoming run.
0 · Reply
TheRhew6
TheRhew6 Dec. 29 at 8:30 PM
$TAK here’s my new winner! I’m in! Let’s run this up good luck to all.
1 · Reply
jlz1
jlz1 Dec. 29 at 5:38 PM
$TAK what is the new price target for TAK? $50?
0 · Reply
FateFinance
FateFinance Dec. 25 at 4:50 AM
$TAK Capital markets will reward execution consistency across macro cycles and demand regimes, with outcomes shaped by timing and discipline. Market patience is not unlimited.
0 · Reply
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 22 at 3:21 AM
$ALMS $TAK https://www.biopharmadive.com/news/takeda-zasocitinib-tyk2-psoriasis-drug-results-nimbus/808237/ Alms is worth $4B There's your low end mc target. 💪😎
0 · Reply
Rajesh100
Rajesh100 Dec. 18 at 10:14 PM
$ALMS $TAK https://stocks.apple.com/Awcjft6ItSa624Pw0bbALeA
0 · Reply
briefingcom
briefingcom Dec. 18 at 1:46 PM
$TAK: Takeda’s Zasocitinib Landmark Phase 3 plaque psoriasis data show promise to deliver clear skin in a once-daily pill, catalyzing a new era of treatment
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:49 PM
Citizens reiterated $PTGX Market Outperform/$102. $TAK $JNJ Citizens said in its note: PTGX has a big decision coming up by mid-2026 when management has to determine whether to opt out of its 50/50 U.S. profit/loss share for rusfertide with Takeda, which would change PTGX's downstream economics. We assume PTGX will opt out to bring in more risk-free cash that the company can deploy to advance its earlier-stage internal pipeline.
0 · Reply
wyoming2020
wyoming2020 Dec. 11 at 11:18 AM
$PDSB might get some interest in Japan with patent $TAK a potential partner there / big multinational with interesting oncology pipeline
3 · Reply
Quantumup
Quantumup Dec. 10 at 2:04 PM
H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20
0 · Reply
prismmarketview
prismmarketview Dec. 8 at 4:33 PM
Protagonist Therapeutics’(NASDAQ: $PTGX) and Takeda (NYSE: $TAK), Rusfertide continues to impress in PV, with Phase 3 VERIFY data showing durable 52-week hematocrit control, a double-digit fold reduction in annual phlebotomy rates, and sustained responses that strengthen its first-in-class profile. https://prismmarketview.com/protagonist-therapeuticss-rusfertide-delivers-durable-results-in-phase-iii/
0 · Reply
SparkyReturns
SparkyReturns Dec. 8 at 4:33 PM
$BIIB I'm surprised some of the large drug companies haven't noticed what ICU is doing.... Check out this investing idea. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again = 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in to ICU for those looking for an investing idea. Cheers! $SNY $TAK $RDY $TEVA
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 11:34 PM
$PTGX $TAK Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera "52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints"
0 · Reply
briefingcom
briefingcom Dec. 5 at 1:48 PM
$TAK: Takeda Pharma and Innovent finalize global oncology partnership for IO and ADC pipeline https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251205043300TAK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply